This was the stock's second consecutive day of gains.

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

Incyte’s shares (currently trading at $60.02) have posted a disappointing 11.8% loss while the S&P 500 was down 1.7%. This ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been given a consensus recommendation of “Hold” by the nineteen ...

Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi ® (tafasitamab) by its Mexican affiliate, Grupo ...

Shares of Incyte Corp. INCY rose 1.39% to $62.78 Monday, on what proved to be an all-around positive trading session for the ...

Incyte’s The Unseen Journey illustrates the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Morgan Stanley lowered the firm’s price target on Incyte (INCY) to $65 from $69 and keeps an Equal Weight rating on the shares. Based on the ...

Researchers from Mass General Brigham developed olfactory tests—in which participants sniff odor labels that have been placed on a card—to assess people’s ability to discriminate, identify and ...